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Abstract
Purpose Identifying intake of synthetic cannabinoids generally requires the metabolism data of the drugs so that appropriate 
metabolite markers can be targeted in urine testing. However, the continuous appearance of new cannabinoids during the last 
decade has made it difficult to keep up with all the compounds including {1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}
(naphthalen-1-yl)methanone (AM1220). In this study, metabolism of AM1220 was investigated with human liver microsomes 
and the fungus Cunninghamella elegans.
Methods Metabolic stability of AM1220 was analysed by liquid chromatography–tandem mass spectrometry in multiple 
reaction monitoring mode after 1 µM incubation in human liver microsomes for 30 min. Tentative structure elucidation of 
metabolites was performed on both human liver microsome and fungal incubation samples using liquid chromatography–
high-resolution mass spectrometry.
Results Half-life of AM1220 was estimated to be 3.7 min, indicating a high clearance drug. Nine metabolites were detected 
after incubating human liver microsomes while seven were found after incubating Cunninghamella elegans, leading to 11 
metabolites in total (five metabolites were common to both systems). Demethylation, dihydrodiol formation, combination 
of the two, hydroxylation and dihydroxylation were the observed biotransformations.
Conclusions Three most abundant metabolites in both human liver microsomes and Cunninghamella elegans were desme-
thyl, dihydrodiol and hydroxy metabolites, despite different isomers of dihydrodiol and hydroxy metabolites in each model. 
These abundant metabolites can potentially be useful markers in urinalysis for AM1220 intake.
Keywords AM1220 · Synthetic cannabinoid · In vitro metabolism · Human liver microsomes · Cunninghamella elegans · 
High resolution mass spectrometry
Introduction
AM1220, or {1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-
3-yl}(naphthalen-1-yl)methanone, is a synthetic cannabinoid 
that was first synthesised in the 1990s to study the structure-
activity relationship of cannabinoid receptors [1]. The can-
nabinoid was shown to have a binding affinity (Ki) of 3.88 
and 73.4 nM to cannabinoid receptor type 1  (CB1) and type 2 
 (CB2) receptors, respectively [2]. Because of the high affin-
ity to cannabinoid receptors, AM1220 began to be sold and 
abused as “herbal products” and “research chemicals” on the 
recreational drug market among the continuous emergence 
of a myriad of new psychoactive substances [3–8].
In these products, AM1220 is usually found together with 
its azepane isomer, [1-(1-methyl-3-azepanyl)-1H-indol-3-yl]
(1-naphthyl)methanone [4, 5], which is suggested to be pre-
sent as a synthetic impurity [4] or due to a rearrangement 
that occurs over time [7]. The presence of the AM1220 
azepane isomer may complicate interpretation of the phar-
macological effects of AM1220, as the azepane isomer itself 
is shown to have binding affinities to  CB1 and  CB2 receptors 
[9].
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For detection of synthetic cannabinoids in humans, 
plasma samples are shown to be useful since the parent 
drugs can be found as they are without modifications [10]. 
However, there are some issues with detection in plasma 
samples. Firstly, the window of detection of the parent drugs 
in blood is short [10, 11]. Secondly, the concentrations of the 
parent drugs in plasma are reported to be lower than those 
of the major metabolites [11]. In addition, plasma samples 
are not always obtainable due to invasiveness of collection 
method, and urine samples are often the preferred choice for 
drug testing. Therefore, suitable methods to analyse urine 
samples are desirable. Nevertheless, synthetic cannabinoids 
are highly lipophilic, and high distribution rate of parent 
drugs for tissue such as fat results in low excretion rate in 
urine. Furthermore, synthetic cannabinoids are extensively 
metabolised in humans and are generally not excreted in 
urine in the parent drug form. Consequently, metabolites 
need to be monitored for detecting synthetic cannabinoids 
in urine specimens.
Metabolism studies of synthetic cannabinoids have been 
performed using several approaches. Human liver micro-
some (HLM) incubation is the most common in  vitro 
approach, and even though not reflective of the metabolism 
in a whole human body, it can generate a wide variety of 
human metabolites with advantages such as low cost and 
larger pools of donors [11–13]. Human hepatocytes provide 
the metabolic profiles closest to the in vivo human data 
[14–16], and animal models such as rats are valuable as a 
source of in vivo data, though not always consistent with 
human findings [17–19]. Incubation with the fungus Cun-
ninghamella elegans (C. elegans) has been shown to pro-
duce similar metabolic profiles to the human system with 
the advantage of low cost and production of large quantity 
of metabolites [20–22]. Cunninghamella elegans is, how-
ever, not suitable for strict absorption-distribution-metabo-
lism-elimination (ADME) studies, since it does not provide 
blood and urine as separate specimens as animal models do. 
The presence and abundance of the metabolites determined 
by these models may not be an accurate representation of 
in vivo metabolites. Thus, the in vitro metabolites should 
be confirmed in human urine, if available, by analysis of 
urine samples obtained from suspected users of synthetic 
cannabinoids, since analysis of human urine from controlled 
administration is difficult at this point without sufficient data 
to ensure safety [11].
To date, there has been no in vitro metabolism study 
of AM1220. There is one in vivo study by Zaitsu et al. 
[10] reporting two metabolites of AM1220 and two more 
potential metabolites in postmortem human plasma and 
urine specimens, respectively, from a fatal intoxication 
case. To complement the in vivo findings, which may have 
been affected by genotype, phenotype and/or inhibition of 
cytochrome P450 (CYP) enzymes by coadministration of 
drug, in vitro metabolism study will be useful [23].
In this study, we report the metabolic stability of AM1220 
based on HLM incubation and tentative structure elucidation 
of AM1220 metabolites obtained from HLM and C. elegans 
incubation. Suitable markers for urinalysis are also sug-
gested. Liquid chromatography–quadrupole time-of-flight 
mass spectrometry (LC–QTOF-MS) was used for analysis 
since high-resolution mass spectrometry has an advantage 
of providing accurate masses, enabling more confident char-
acterisation of metabolites [24].
Materials and methods
Chemicals and reagents
AM1220 was obtained from Cayman Chemical (Ann Arbor, 
MI, USA). UR-144 was synthesised in-house following the 
methods previously reported [25, 26] and characterised by 
mass spectrometry (MS) and 1D and 2D nuclear magnetic 
resonance spectroscopy techniques. Fifty-donor HLM pool, 
NADPH system solution A and NADPH system solution B 
were from Corning (Corning, NY, USA). Liquid chromatog-
raphy–mass spectrometry (LC–MS) grade acetonitrile was 
obtained from Honeywell (Muskegon, MI, USA). Reagent 
grade dichloromethane and sodium chloride were purchased 
from Chemsupply (Gilman, SA, Australia). LC–MS grade 
formic acid was obtained from Sigma-Aldrich (St. Louis, 
MO, USA). Cunninghamella elegans ATCC 10028b was 
from Cryosite Ltd. (South Granville, NSW, Australia). Glyc-
erol and potassium dihydrogen phosphate and dipotassium 
hydrogen phosphate were from Ajax Chemicals (Auburn, 
NSW, Australia). Potato dextrose agar, glucose, peptone, and 
yeast extract were purchased from Oxoid Australia (Ade-
laide, SA, Australia).
Metabolic stability
AM1220 solution in acetonitrile/phosphate buffer (40 µM, 
pH 7.4, 25 µL, 0.1% acetonitrile), phosphate buffer (0.1 M, 
pH 7.4, 855 µL), NADPH-A (50 µL) and NADPH-B (20 
µL) were mixed in an Eppendorf tube, to which HLM (50 
µL = 1 mg protein) was added. The final concentration of 
AM1220 in the mixture was 1 µM with 0.003% acetonitrile. 
The mixture was incubated in triplicate at 37 °C in a shak-
ing water bath. At time 0, 3, 8, 13, 20 and 30 min, a 100-µL 
aliquot was removed and placed into 100 µL ice-cold ace-
tonitrile to quench the reaction. The mixture was centrifuged 
at 16,060 × g for 10 min and filtered with a 0.22 µm filter. 
Ten microliters of the filtrate was diluted in 990 µL water/
acetonitrile (70:30, v/v) and 10 µL was injected into liquid 
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chromatography–triple quadrupole mass spectrometer in 
triplicate.
Chromatographic separation was performed on an Agilent 
1290 LC system with an Agilent Zorbax Eclipse XDBC18 
analytical column (150 × 4.6 mm i.d., particle size 5 μm) 
(Agilent Technologies, Santa Clara, CA, USA). The mobile 
phase consisted of 0.1% formic acid in water (A) and 0.1% 
formic acid in acetonitrile (B). The gradient system was as 
follows: 30% B until 1 min, ramped to 40% B over 15 min, 
95% B at 16.01 min and held until 19.1 min, ramped down to 
30% B at 19.11 min and held until 23 min. The flow rate was 
0.4 mL/min and the column temperature was kept at 30 °C.
Mass spectrometry was run in multiple reaction moni-
toring mode on an Agilent 6490 Triple Quadrupole mass 
spectrometer with electrospray ionisation (ESI) source in 
positive ion mode (Agilent Technologies). Two transitions 
(m/z 383 → 286 and m/z 383 → 98) were monitored with 
fragmentor voltage of 380 V and collision energy of 20 and 
50 eV, respectively.
In vitro microsomal half-life (t1/2) of AM1220 was cal-
culated based on the plot of natural log of percentage of the 
drug remaining against time. Percentage of the drug remain-
ing was calculated by dividing the peak area of the drug 
remaining at each time point by the peak area of the drug 
at time 0 min and multiplying by 100%. The slope of the 
line (−k) was used to give t1/2 = ln2/k. Intrinsic clearance 
 (CLint, in mL/min/kg) was calculated based on the following 
formula [27]:
where t1/2 (the only variable in the equation) was substituted.
Hepatic clearance  (CLH) and hepatic extraction ratio (EH) 
were calculated based on the well-stirred model from the 
following formulae without considering blood protein and 
microsome binding [27, 28]. The 21 mL/min/kg was used 
for human hepatic blood flow (QH) [27].
Tentative structure elucidation of metabolites
Human liver microsome incubation
The incubation mixture was prepared as described for the 
metabolic stability study using 1 mg/mL, i.e., 2.61 mM 
AM1220 solution (final concentration of acetonitrile was 
CLint =
ln 2
t1∕2
×
mL of incubation
mg of microsomes
×
45 mg of microsomes
g of liver
×
20 g of liver
kg of body weight
,
CLH =
QH × CLint
QH + CLint
,
EH =
CLH
QH
.
0.2%). The mixture was incubated at 37 °C in a shaking 
water bath for 1 h. The reaction was quenched by add-
ing ice-cold acetonitrile (1 mL) to the mixture and it was 
centrifuged at 16,060 × g for 10 min. The sample was fil-
tered (0.22 µm) and injected to LC–QTOF-MS. A control 
sample without HLM, a control without AM1220 and a 
positive control using UR-144 were also incubated and 
analysed.
Fungus incubation
Cunninghamella elegans was cultured on potato dextrose 
agar plates at 27 °C for 5 days. The mycelia of the fungus 
were mixed in sterile physiological saline solution (1 plate 
of mycelia/5 mL). Growth medium was prepared [29], and 
1.5 mL of the fungus solution was added to 100 mL of 
medium in a conical flask. The culture was incubated for 
48 h at 26 °C and 180 rpm on an Infors HT Multitron 
rotary shaker (In Vitro Technologies, Noble Park North, 
VIC, Australia). AM1220 (1 mg in 0.5 mL acetonitrile) 
was added to the flask and incubated for another 72 h. 
The solution was filtered, extracted with dichloromethane 
(3 × 50 mL) and evaporated using a rotary evaporator and a 
vacuum pump. The sample was reconstituted in 2 mL ace-
tonitrile, which was further diluted in acetonitrile tenfold. 
A control without fungus and a control without AM1220 
were also incubated.
LC–QTOF‑MS
Chromatographic equipment and conditions were the same 
as described above for metabolic stability section, except 
for the following. The gradient started with 30% B, and 
was held until 1 min, ramped up to 40% B over 19 min, 
90% B at 21 min, held until 24 min, ramped down to 30% 
B at 25 min and held until 30 min for re-equilibration. 
Injection volume was 2 µL for scan analysis and 10 µL for 
product ion scan analysis.
Mass spectra were acquired on an Agilent 6510 Accu-
rate Mass Q-TOF mass spectrometer, equipped with a dual 
ESI source (Agilent Technologies). The parameters were 
as follows: scanning mass range, m/z 100–1000 (MS), m/z 
80–1000 (MS/MS); capillary voltage, 3500 V; nebulizer 
pressure, 30 psig; gas temperature, 325 °C; gas flow, 5 L/
min; fragmentor voltage, 160 V; collision energy for prod-
uct ion scan analysis, 10, 20 and 40 eV; skimmer voltage, 
65 V. Mass calibration was performed with the mixture 
provided by the manufacturer. Real-time mass calibration 
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was enabled using the following reference masses: m/z 
121.0509 and 922.0098.
Additional MS analyses were performed on an Agilent 
6550A iFunnel Q-TOF with a dual AJS ESI source (Agilent 
Technologies) operated with the same parameters as above 
except for the following: gas temperature, 290 °C; gas flow, 
11 L/min; sheath gas temperature, 350 °C; sheath gas flow, 
11 L/min; injection volume for product ion scan analysis, 
2 µL.
Extracted ion chromatograms and mass spectra were 
analysed using Agilent MassHunter Workstation Soft-
ware Qualitative Analysis (version B.06.00). A personal 
compound database and library (PCDL) with known and 
potential metabolites of the drug was created with Agilent 
MassHunter PCDL Manager (version B.04.00) to search for 
the metabolites. Search parameters were as follows: mass 
tolerance, 20 ppm; maximum number of matches, 8; abso-
lute peak area ≥ 5000. The criteria for metabolites were as 
follows: mass error of the protonated molecules ≤ 5 ppm; 
consistent fragmentation pattern with proposed structure; 
reasonable retention time relative to other biotransforma-
tions; absence of the metabolite in controls.
Results
Metabolic stability
In vitro t1/2 of AM1220 was calculated to be 3.7 ± 0.4 min 
[mean ± standard deviation (SD), n = 3]. From the calculated 
t1/2 value,  CLint,  CLH and EH were estimated to be 168.5 mL/
min/kg, 18.7 mL/min/kg, and 0.89, respectively. The per-
centage of drug remaining at each time point, used for cal-
culation, is shown in Table 1.
Tentative structure elucidation of metabolites
Chromatograms of AM1220 and its metabolites after HLM 
and C. elegans incubation are shown in Fig. 1. The prod-
uct ion spectra and the suggested fragmentation patterns 
of AM1220 and the metabolites are shown in Fig. 2. The 
proposed metabolic pathway of AM1220 in HLM and C. 
elegans incubation is compared with the in vivo postmortem 
human data in the literature (Fig. 3). Table 2 lists all the 
metabolites with retention times, elemental compositions, 
exact mass, accurate mass, mass errors, diagnostic product 
ions and chromatographic peak areas.
Human liver microsomes
Nine metabolites were detected in HLM incubation and 
assigned as H1–H9 in the order of retention time (Fig. 1). The 
following metabolites were detected; dihydrodiol (H2, H3, 
H5), dihydrodiol with demethylation (H1, H4), demethyla-
tion (H7), hydroxylation (H8, H9) and dihydroxylation (H6). 
The mass errors of the metabolites compared with the pro-
posed elemental compositions were ≤ 2.17 ppm (Table 2). The 
top three abundant metabolites based on the peak area were 
dihydrodiol (H3), demethylation (H7) and hydroxylation (H8) 
metabolites.
Fungus C. elegans
Seven metabolites were found after C. elegans incubation and 
assigned as F1–F7 (Fig. 1). Dihydrodiol (F1–F3), demeth-
ylation (F6) and hydroxylation (F4, F5, F7) metabolites were 
identified. Five of them were the same metabolites as HLM 
metabolites (Table 2); dihydrodiol (H2 and F1, H3 and F2, H5 
and F3), demethylation (H7 and F6) and hydroxylation (H8 
and F7) were common metabolites between HLM and fungus 
metabolism. The mass errors were all ≤ 1.15 ppm. The three 
most abundant metabolites were hydroxylation (F4), dihydro-
diol (F1) and demethylation (F6) products.
Discussion
Metabolic stability
In vitro t1/2 of AM1220 was 3.7 min and this belongs to the 
class of high clearance compounds [30]. The estimated EH 
Table 1  Average percentage of the drug remaining and relative stand-
ard deviation (RSD, n = 3) at each time point for three human liver 
microsome (HLM) incubation samples for metabolic stability study
Time (min) Average percentage of the 
drug remaining (%)
RSD (%)
Sample 1 0 100 0
3 44.4 0.9
8 14.9 0.6
13 4.6 2.1
20 1.0 7.0
30 0.2 14.7
Sample 2 0 100 0
3 46.9 0.3
8 14.9 1.0
13 5.3 1.1
20 1.0 3.1
30 0.3 30.2
Sample 3 0 100 0
3 55.9 1.5
8 18.9 0.2
13 6.7 0.6
20 2.0 4.2
30 0.8 4.6
439Forensic Toxicology (2018) 36:435–446 
1 3
of 0.89 also indicates high extraction, suggesting the com-
pound to be highly susceptible to hepatic metabolism [31]. 
These findings are in line with other synthetic cannabinoids 
and account for the extensive metabolism of cannabinoids 
[15, 32, 33].
Tentative structure elucidation of metabolites
Nine and seven metabolites were detected after incubation 
of AM1220 with HLM and fungus, respectively. Based on 
the retention times and the fragmentation patterns of the 
metabolites, five of them were considered identical and 
hence a total of 11 metabolites were found from two in vitro 
models (Table 2). The tentative structure elucidation of these 
metabolites is described below.
Hydroxylation
Four hydroxylated metabolites were detected at m/z 399. 
F4 and F5 showed product ions at m/z 171 and 302, which 
were 16 amu higher than the unchanged naphthoyl moiety 
(m/z 155) and 1-methyl-3-naphthoylindole (m/z 286), respec-
tively, indicating hydroxylation at the naphthalene moiety. 
Other product ions at m/z 98 and 112 confirmed the piperi-
dine moiety to be unaltered. H8 was shown to be hydroxy-
lated at the methylpiperidine moiety by the intact product 
ions at m/z 127, 155, and 286, indicative of the unmodified 
indole and naphthalene moieties. The absence of ions at m/z 
98 and 112 also indicated the modification of the methyl-
piperidine ring. F7 eluted at the same retention time as H8, 
but only showed the product ions at m/z 127 and 155 without 
286. Without the ion at m/z 286, hydroxylation could have 
occurred at either indole or piperidine moiety. However, it 
was considered to be the identical metabolite as H8 because 
of the same retention time and the fact that the ions at m/z 
98 and 112 were absent, which were seen for all the other 
metabolites without modification to the piperidine moiety 
and the parent drug. H9 was characterised by the unchanged 
naphthalene (m/z 127, 155) and unchanged piperidine (m/z 
98, 112), indicating the location of hydroxylation to be the 
indole ring.
Dihydroxylation
A dihydroxy metabolite (H6) was found at m/z 415, which 
resulted from further oxidation of H8. The fragment ions at 
m/z 127, 155 and 286 are in common with the parent drug, 
indicating the intact naphthoylindole moiety. The ion at m/z 
144 indicated the (1-methyl-2-piperidinyl)methyl moiety to 
be the site of dihydroxylation. It is interesting to note that an 
abundant fragment ion at m/z 272 was observed. While the 
presence of the ion does not contradict the aforementioned 
position of dihydroxylation, this ion was formed from a dif-
ferent fragmentation pattern from the parent drug.
Dihydrodiol formation
Three dihydrodiol metabolites (H2/F1, H3/F2 and H5/F3) 
were observed with m/z 417. All three metabolites showed 
the same fragment ions: m/z 98, 112, 171, 189 and 320. The 
ions at m/z 98 and 112 show the unchanged piperidine moi-
ety while m/z 189 and 320 indicate dihydrodiol formation at 
naphthalene moiety with the former losing a water molecule 
to form m/z 171.
Fig. 1  Combined extracted 
ion chromatograms, from total 
ion current chromatogram, of 
AM1220 and its metabolites in 
human liver microsome (HLM) 
and fungus incubation
0
62.5 x 10
Time (min)
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
H1
H3
H5H4
H2
H6
H7
H8 H9
AM1220
In
te
ns
ity
 (c
ou
nt
s)
HLM
H4 H9
0
71.6 x 10
Time (min)
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
In
te
ns
ity
 (c
ou
nt
s)
F1 F2 F3 F4
F5 F6 F7
AM1220
Fungus
F2
F3
F5 F7
5 16
54.5 11 1510.5
440 Forensic Toxicology (2018) 36:435–446
1 3
Dihydrodiol-
desmethyl
H1/(H4)
98.0964
171.0439
0
50000 417.2165
112.1121
320.1276189.0545
100 150 200 250 300 350 400
In
te
ns
ity
 
(c
ou
nt
s)
m/z
0
8000 171.0438
98.0964 189.0544 403.2002
84.0803
320.1273
100 150 200 250 300 350 400
In
te
ns
ity
 
(c
ou
nt
s)
m/z
Dihydrodiol
H2/H3/H5/
F1/F2/F3
0
2500 112.1119
383.2107155.0487 286.1222
127.0529
100 150 200 250 300 350 400
98.0965
In
te
ns
ity
 
(c
ou
nt
s)
m/z
AM1220
144.1031
0
200 155.0495
272.1041 415.2009
127.0542
286.1233
100 150 200 250 300 350 400
In
te
ns
ity
 
(c
ou
nt
s)
m/z
Dihydroxy
H6
Desmethyl
H7/F6
Hydroxy
H8/(F7)
0
2000
155.0488
399.2061
127.0544
286.1260
100 150 200 250 300 350 400
In
te
ns
ity
 
(c
ou
nt
s)
m/z
98.0945
127.0536
0
200 155.0487
399.2010
112.1103
100 150 200 250 300 350 400
In
te
ns
ity
 
(c
ou
nt
s)
m/z
Hydroxy
H9
0
80
112.1109
98.0990
171.0423 302.1215
100 150 200 250 300 350 400
399.2032
m/z
In
te
ns
ity
 
(c
ou
nt
s)
Hydroxy
F4/F5
0
5000
155.0492
272.1066
98.0964
127.0544
100 150 200 250 300 350
369.1952
84.0807
In
te
ns
ity
 
(c
ou
nt
s)
m/z
N
O
N112.1121
98.0964
155.0491
127.0542
286.1226
N
O
NH
98.0964
155.0491
127.0542
272.1070
84.0808
155.0491
127.0542
286.1226
N
O
N
OH
N
O
N
OH
OH
155.0491
127.0542
272.1070
144.1019
286.1226
N
O
N
OH
112.1121
155.0491
127.0542
98.0964
112.1121
98.0964
171.0441
302.1176
N
O
N
OH
N
O
N
OH
OH
112.1121
98.0964
320.1281
189.0546
171.0441
-H2O
N
O
NH
OH
OH
98.0964
84.0808
320.1281
189.0546
171.0441
-H2O
-H2O
385.1911
441Forensic Toxicology (2018) 36:435–446 
1 3
Demethylation
A metabolite demethylated at the piperidine nitrogen (H7/
F6) was detected at m/z 369. The product ions at m/z 127 
and 155 were retained as the naphthalene moiety is intact. 
The fragment ions at m/z 98 and 272 were generated by 
N-dealkylation of indole, corresponding to a demethyl-
ated piperidine moiety and the unaltered naphthoylindole, 
respectively (Fig. 2). The product ion at m/z 98 further lost 
a methylene moiety to form the ion at m/z 84. The lack of 
product ion at m/z 112 also supports demethylation of the 
methylpiperidine moiety.
Dihydrodiol formation and demethylation
Two metabolites at m/z 403 (H1, H4) were found to have 
undergone both dihydrodiol formation at the naphthalene 
ring and demethylation of the methylpiperidine moiety. For 
H1, the combination of the product ions at m/z 171, 189 
and 320 indicates the formation of dihydrodiol at the naph-
thalene moiety, whereas the ions at m/z 84 and 98 without 
112 reflect a demethylated piperidine ring. In fact, H4 did 
not show the fragment ion at m/z 189, but this is probably 
because the dihydrodiol at a particular position is less stable 
and easily loses a water molecule [34]. The hypothesis is 
supported by the observation that the fragment ion at m/z 
385, resulting from water loss of the molecule, is prominent 
in H4.
Comparison of AM1220 metabolites in HLM and  
C. elegans with in vivo human metabolites
Out of nine HLM and seven fungal metabolites detected in 
this study, five metabolites were found to be identical, i.e., 
more than 50% of HLM and fungal metabolites were the 
same as each other. In terms of the biotransformations of 
AM1220, dihydrodiol formation, demethylation and hydrox-
ylation were the common transformations between HLM and 
fungal metabolites. HLM additionally showed the transfor-
mations by dihydroxylation and combinations of dihydro-
diol formation and demethylation. Overall, metabolism of 
AM1220 by HLM and C. elegans was highly consistent.
Cunninghamella elegans is known to contain CYP509A1, 
closely related to the CYP51 family [35], and it can per-
form a number of reactions including both phase I and 
phase II biotransformations [36]. Enzymes responsible for 
hydroxylation, N-demethylation, sulfation, glucuronidation, 
glycosylation, and glutathione conjugation have been indi-
cated to be present [37], and recently, the presence of 
CYP3A4 in C. elegans was indicated [38]. In addition, the 
fungus has facilitated some biotransformations, which were 
catalysed by CYP1A2, CYP2C9, CYP2C19 and CYP2D6 
in human metabolism [20, 39–43]. Although the enzymes 
responsible for the metabolic transformations of AM1220 
in HLM or C. elegans are unknown, the presence of similar 
enzymes in both models is likely the factor for their high 
consistency.
To date, the study by Zaitsu et al. [10] is the only one 
reporting the in vivo human metabolites of AM1220. In the 
study, four metabolites were detected from a fatal case of 
intoxication; hydroxylation, dihydroxylation and N-dealkyla-
tion in plasma and N-dealkylation followed by hydroxy-
lation in urine (Fig. 3). It should be noted, however, that 
metabolites of N-dealkylation and N-dealkylation followed 
by hydroxylation were not confirmed to have formed from 
AM1220 because AM-2232, which also contains a naph-
thoylindole moiety and hence another potential source of 
these metabolites, was also detected in plasma.
Out of the four metabolites, N-dealkylation and 
N-dealkylation followed by hydroxylation were not observed 
after either HLM or C. elegans incubation. Dihydroxylation 
was detected in HLM incubation (H6), yet the positions of 
hydroxy groups were different; dihydroxylation took place 
at the piperidine moiety in H6, while one hydroxylation at 
the naphthalene moiety and another at either the indole or 
piperidine moiety in the plasma metabolite. The hydroxy-
lated metabolite is the only metabolite potentially in com-
mon with HLM incubation, as it may be identical to H9 
based on the mass fragmentation pattern. The inconsistency 
between the in vitro and in vivo metabolites may be due to 
the genotype/phenotype and/or the coadministration of CYP 
enzyme inhibitor in this fatal case [23]. Another hypothesis 
is that AM1220 had not been sufficiently metabolised before 
the death, leading to less metabolites with an incomplete 
metabolic pattern. The higher concentration of AM1220 in 
plasma than its potential N-dealkylated metabolite is in line 
with this hypothesis (hydroxy and dihydroxy metabolites 
were not quantified), as well as the detection of hydroxy 
and dihydroxy metabolites in plasma despite their absence 
in urine [10]. For these reasons, it would be ideal to compare 
the in vitro metabolism data with multiple in vivo data.
Suggested markers
The three most abundant metabolites in HLM and fungus 
incubations were dihydrodiol (H3), demethylation (H7) and 
hydroxylation at the piperidine moiety (H8), and hydroxy-
lation at the naphthalene moiety (F4), dihydrodiol (F1) and 
demethylation (F6), respectively. Based on the high abun-
dance observed in vitro, these metabolites could be potential 
Fig. 2  Product ion spectra of AM1220 and its metabolites at colli-
sion energy of 20 eV, and proposed metabolite structures with exact 
masses of fragmentation. Metabolites in brackets did not show all the 
product ions. The exact locations of dihydrodiol groups in (F1–F3 
and H1–H5) were not determined
◂
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in vivo markers of AM1220 intake. The desmethyl metab-
olite and hydroxy metabolite at the piperidine moiety are 
particularly interesting as the same transformation pathways 
were predominant for AM1241, an analogue of AM1220 
with the naphthalene moiety replaced by 2-iodo-5-nitrophe-
nyl group, in HLM and rat microsomes incubations [32]. The 
dihydrodiol metabolites are also promising, as dihydrodiol 
and hydroxy metabolites were the most abundant metabo-
lites of AM2201 in authentic human urine samples, when 
excluding oxidative defluorination [34]. Since AM1220 does 
not undergo oxidative defluorination, dihydrodiol formation 
may be an abundant in vivo metabolic pathway.
Conclusions
A potent synthetic cannabinoid AM1220 was incubated 
in HLM and C. elegans to elucidate the structures of the 
in vitro metabolites. Metabolic stability of AM1220 was 
estimated from HLM incubation and the estimated in vitro 
half-life and hepatic extraction ratio indicated AM1220 to 
be a high clearance drug. LC–QTOF-MS analysis of HLM 
and C. elegans samples resulted in detection of a total of 
11 metabolites (nine and seven metabolites in respective 
samples) and they consisted of hydroxy, dihydroxy, des-
methyl, dihydrodiol, and dihydrodiol-desmethyl metabo-
lites. The results did not match the in vivo metabolism 
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previously reported; however it should be noted that the 
results in the study were based on a single postmortem 
sample. Based on the in vitro data, hydroxy, desmethyl 
and dihydrodiol metabolites are deemed suitable urinary 
markers of AM1220 intake. These data should help toxi-
cological and clinical laboratories to identify AM1220 
consumption from human urine samples.
Compliance with ethical standards 
Conflict of interest The authors declare no conflicts of interest.
Ethical approval This article does not contain any studies with human 
participants or animals performed by any of the authors.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. D’Ambra TE, Eissenstat MA, Abt J, Ackerman JH, Bacon ER, 
Bell MR, Carabateas PM, Josef KA, Kumar V, Weaver Iii JD, 
Arnold R, Casiano FM, Chippari SM, Haycock DA, Kuster JE, 
Luttinger DA, Stevenson JI, Ward SJ, Hill WA, Khanolkar A, 
Makriyannis A (1996) C-Attached aminoalkylindoles: potent can-
nabinoid mimetics. Bioorg Med Chem Lett 6:17–22. https ://doi.
org/10.1016/0960-894X(95)00560 -G
 2. Makriyannis A, Deng H (2008) Cannabimimetic indole deriva-
tives. US 2008/0090871 A1
 3. Uchiyama N, Kawamura M, Kikura-Hanajiri R, Goda Y 
(2012) Identification of two new-type synthetic cannabinoids, 
N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide (APICA) 
and N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (API-
NACA), and detection of five synthetic cannabinoids, AM-1220, 
AM-2233, AM-1241, CB-13 (CRA-13), and AM-1248, as 
designer drugs in illegal products. Forensic Toxicol 30:114–125. 
https ://doi.org/10.1007/s1141 9-012-0136-7
 4. Kneisel S, Bisel P, Brecht V, Broecker S, Müller M, Auwärter 
V (2012) Identification of the cannabimimetic AM-1220 and its 
azepane isomer (N-methylazepan-3-yl)-3-(1-naphthoyl)indole in 
a research chemical and several herbal mixtures. Forensic Toxicol 
30:126–134. https ://doi.org/10.1007/s1141 9-012-0137-6
 5. Nakajima J, Takahashi M, Seto T, Kanai C, Suzuki J, Yoshida 
M, Uemura N, Hamano T (2013) Analysis of azepane isomers 
of AM-2233 and AM-1220, and detection of an inhibitor of fatty 
acid amide hydrolase [3′-(aminocarbonyl)(1,1′-biphenyl)-3-yl]-
cyclohexylcarbamate (URB597) obtained as designer drugs in the 
Tokyo area. Forensic Toxicol 31:76–85. https ://doi.org/10.1007/
s1141 9-012-0169-y
 6. Salomone A, Luciano C, Di Corcia D, Gerace E, Vincenti M 
(2014) Hair analysis as a tool to evaluate the prevalence of syn-
thetic cannabinoids in different populations of drug consumers. 
Drug Test Anal 6:126–134. https ://doi.org/10.1002/dta.1556
 7. Langer N, Lindigkeit R, Schiebel H-M, Ernst L, Beuerle T (2014) 
Identification and quantification of synthetic cannabinoids in 
‘spice-like’ herbal mixtures: a snapshot of the German situa-
tion in the autumn of 2012. Drug Test Anal 6:59–71. https ://doi.
org/10.1002/dta.1499
 8. Blakey K, Boyd S, Atkinson S, Wolf J, Slottje PM, Goodchild K, 
McGowan J (2016) Identification of the novel synthetic cannabi-
mimetic 8-quinolinyl 4-methyl-3-(1-piperidinylsulfonyl)benzoate 
(QMPSB) and other designer drugs in herbal incense. Forensic Sci 
Int 260:40–53. https ://doi.org/10.1016/j.forsc iint.2015.12.001
 9. Nakajima J, Takahashi M, Uemura N, Seto T, Fukaya H, Suzuki J, 
Yoshida M, Kusano M, Nakayama H, Zaitsu K, Ishii A, Moriyasu 
T, Nakae D (2015) Identification of N, N-bis(1-pentylindol-3-yl-
carboxy)naphthylamine (BiPICANA) found in an herbal blend 
product in the Tokyo metropolitan area and its cannabimimetic 
effects evaluated by in vitro  [35S]GTPγS binding assays. Forensic 
Toxicol 33:84–92. https ://doi.org/10.1007/s1141 9-014-0253-6
 10. Zaitsu K, Nakayama H, Yamanaka M, Hisatsune K, Taki K, Asano 
T, Kamata T, Katagai M, Hayashi Y, Kusano M, Tsuchihashi H, 
Ishii A (2015) High-resolution mass spectrometric determination 
of the synthetic cannabinoids MAM-2201, AM-2201, AM-2232, 
and their metabolites in postmortem plasma and urine by LC/Q-
TOFMS. Int J Legal Med 129:1233–1245. https ://doi.org/10.1007/
s0041 4-015-1257-4
 11. Diao X, Huestis MA (2017) Approaches, challenges, and advances 
in metabolism of new synthetic cannabinoids and identification 
of optimal urinary marker metabolites. Clin Pharmacol Ther 
101:239–253. https ://doi.org/10.1002/cpt.534
 12. Kim U, Jin MJ, Lee J, Han SB, In MK, Yoo HH (2012) Tenta-
tive identification of phase I metabolites of HU-210, a classical 
synthetic cannabinoid, by LC-MS/MS. J Pharm Biomed Anal 
64-65:26–34. https ://doi.org/10.1016/j.jpba.2012.02.007
 13. Kim JH, Kim HS, Kong TY, Lee JY, Kim JY, In MK, Lee HS 
(2016) In vitro metabolism of a novel synthetic cannabinoid, 
EAM-2201, in human liver microsomes and human recombinant 
cytochrome P450s. J Pharm Biomed Anal 119:50–58. https ://doi.
org/10.1016/j.jpba.2015.11.023
 14. Wohlfarth A, Castaneto MS, Zhu M, Pang S, Scheidweiler KB, 
Kronstrand R, Huestis MA (2015) Pentylindole/pentylindazole 
synthetic cannabinoids and their 5-fluoro analogs produce differ-
ent primary metabolites: metabolite profiling for AB-PINACA and 
5F-AB-PINACA. AAPS J 17:660–677. https ://doi.org/10.1208/
s1224 8-015-9721-0
 15. Diao X, Scheidweiler KB, Wohlfarth A, Pang S, Kronstrand R, 
Huestis MA (2016) In vitro and in vivo human metabolism of 
synthetic cannabinoids FDU-PB-22 and FUB-PB-22. AAPS J 
18:455–464. https ://doi.org/10.1208/s1224 8-016-9867-4
 16. Diao X, Carlier J, Zhu M, Pang S, Kronstrand R, Scheidweiler 
KB, Huestis MA (2017) In vitro and in vivo human metabolism 
of a new synthetic cannabinoid NM-2201 (CBL-2201). Forensic 
Toxicol 35:20–32. https ://doi.org/10.1007/s1141 9-016-0326-9
 17. Jang M, Yang W, Shin I, Choi H, Chang H, Kim E (2014) Deter-
mination of AM-2201 metabolites in urine and comparison 
with JWH-018 abuse. Int J Legal Med 128:285–294. https ://doi.
org/10.1007/s0041 4-013-0884-x
 18. Grigoryev A, Melnik A, Savchuk S, Simonov A, Rozhanets V 
(2011) Gas and liquid chromatography-mass spectrometry studies 
on the metabolism of the synthetic phenylacetylindole cannabi-
mimetic JWH-250, the psychoactive component of smoking mix-
tures. J Chromatogr B 879:2519–2526. https ://doi.org/10.1016/j.
jchro mb.2011.07.004
 19. Kevin RC, Lefever TW, Snyder RW, Patel PR, Fennell TR, Wiley 
JL, McGregor IS, Thomas BF (2017) In vitro and in vivo pharma-
cokinetics and metabolism of synthetic cannabinoids CUMYL-
PICA and 5F-CUMYL-PICA. Forensic Toxicol 35:333–347. https 
://doi.org/10.1007/s1141 9-017-0361-1
 20. Watanabe S, Kuzhiumparambil U, Winiarski Z, Fu S (2016) Bio-
transformation of synthetic cannabinoids JWH-018, JWH-073 and 
446 Forensic Toxicology (2018) 36:435–446
1 3
AM2201 by Cunninghamella elegans. Forensic Sci Int 261:33–42. 
https ://doi.org/10.1016/j.forsc iint.2015.12.023
 21. Watanabe S, Kuzhiumparambil U, Winiarski Z, Fu S (2016) Data 
on individual metabolites of synthetic cannabinoids JWH-018, 
JWH-073 and AM2201 by Cunninghamella elegans. Data Brief 
7:332–340. https ://doi.org/10.1016/j.dib.2016.02.039
 22. Watanabe S, Kuzhiumparambil U, Nguyen MA, Cameron J, Fu 
S (2017) Metabolic profile of synthetic cannabinoids 5F-PB-22, 
PB-22, XLR-11 and UR-144 by Cunninghamella elegans. AAPS 
J 19:1148–1162. https ://doi.org/10.1208/s1224 8-017-0078-4
 23. Steuer AE, Williner E, Staeheli S, Kraemer T (2017) Studies on 
the metabolism of the fentanyl-derived designer drug butyrfen-
tanyl in human in vitro liver preparations and authentic human 
samples using liquid chromatography-high resolution mass spec-
trometry (LC-HRMS). Drug Test Anal 9:1085–1092. https ://doi.
org/10.1002/dta.2111
 24. Pasin D, Cawley A, Bidny S, Fu S (2017) Current applications 
of high-resolution mass spectrometry for the analysis of new 
psychoactive substances: a critical review. Anal Bioanal Chem 
409:5821–5836. https ://doi.org/10.1007/s0021 6-017-0441-4
 25. Nunomoto S, Kawakami Y, Yamashita Y, Takeuchi H, Eguchi S 
(1990) Regioselectivity control in alkylation reactions of indolyl 
ambident anion. J Chem Soc Perkin Trans 1 1990:111–114. https 
://doi.org/10.1039/P1990 00001 11
 26. Okauchi T, Itonaga M, Minami T, Owa T, Kitoh K, Yoshino H 
(2000) A general method for acylation of indoles at the 3-position 
with acyl chlorides in the presence of dialkylaluminum chloride. 
Org Lett 2:1485–1487. https ://doi.org/10.1021/ol005 841p
 27. Obach RS (1999) Prediction of human clearance of twenty-
nine drugs from hepatic microsomal intrinsic clearance data: an 
examination of in vitro half-life approach and nonspecific bind-
ing to microsomes. Drug Metab Dispos 27:1350–1359 (PMID: 
10534321)
 28. Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, 
Sugiyama Y (2001) Prediction of human hepatic clearance from 
in vivo animal experiments and in vitro metabolic studies with 
liver microsomes from animals and humans. Drug Metab Dispos 
29:1316–1324 (PMID: 11560875)
 29. Choudhary MI, Khan NT, Musharraf SG, Anjum S, Atta-ur-Rah-
man (2007) Biotransformation of adrenosterone by filamentous 
fungus, Cunninghamella elegans. Steroids 72:923–929. https ://
doi.org/10.1016/j.stero ids.2007.08.002
 30. McNaney CA, Drexler DM, Hnatyshyn SY, Zvyaga TA, Knipe 
JO, Belcastro JV, Sanders M (2008) An automated liquid chro-
matography-mass spectrometry process to determine metabolic 
stability half-life and intrinsic clearance of drug candidates by 
substrate depletion. Assay Drug Dev Technol 6:121–129. https ://
doi.org/10.1089/adt.2007.103
 31. Lavé T, Dupin S, Schmitt C, Valles B, Ubeaud G, Chou RC, Jaeck 
D, Coassolo P (1997) The use of human hepatocytes to select 
compounds based on their expected hepatic extraction ratios in 
humans. Pharm Res 14:152–155. https ://doi.org/10.1023/a:10120 
36324 237
 32. Wood JT, Smith DM, Janero DR, Zvonok AM, Makriyannis A 
(2013) Therapeutic modulation of cannabinoid lipid signaling: 
metabolic profiling of a novel antinociceptive cannabinoid-2 
receptor agonist. Life Sci 92:482–491. https ://doi.org/10.1016/j.
lfs.2012.06.019
 33. Mardal M, Gracia-Lor E, Leibnitz S, Castiglioni S, Meyer MR 
(2016) Toxicokinetics of new psychoactive substances: plasma 
protein binding, metabolic stability, and human phase I metabo-
lism of the synthetic cannabinoid WIN 55,212-2 studied using in 
vitro tools and LC-HR-MS/MS. Drug Test Anal 8:1039–1048. 
https ://doi.org/10.1002/dta.1938
 34. Sobolevsky T, Prasolov I, Rodchenkov G (2012) Detection of uri-
nary metabolites of AM-2201 and UR-144, two novel synthetic 
cannabinoids. Drug Test Anal 4:745–753. https ://doi.org/10.1002/
dta.1418
 35. Wang R-F, Cao W-W, Khan AA, Cerniglia CE (2000) Cloning, 
sequencing, and expression in Escherichia coli of a cytochrome 
P450 gene from Cunninghamella elegans. FEMS Microbiol Lett 
188:55–61. https ://doi.org/10.1111/j.1574-6968.2000.tb091 68.x
 36. Asha S, Vidyavathi M (2009) Cunninghamella–a microbial model 
for drug metabolism studies—a review. Biotechnol Adv 27:16–29. 
https ://doi.org/10.1016/j.biote chadv .2008.07.005
 37. Zhang D, Yang Y, Leakey JEA, Cerniglia CE (1996) Phase I and 
phase II enzymes produced by Cunninghamella elegans for the 
metabolism of xenobiotics. FEMS Microbiol Lett 138:221–226. 
https ://doi.org/10.1111/j.1574-6968.1996.tb081 61.x
 38. Dube AK, Kumar MS (2017) Biotransformation of bromhexine 
by Cunninghamella elegans, C. echinulata and C. blakesleeana. 
Braz J Microbiol 48:259–267. https ://doi.org/10.1016/j.
bjm.2016.11.003
 39. Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran 
CL, Endres GW, James LP, Hollenberg PF, Prather PL, Radom-
inska-Pandya A, Moran JH (2012) Cytochrome P450-mediated 
oxidative metabolism of abused synthetic cannabinoids found in 
K2/Spice: identification of novel cannabinoid receptor ligands. 
Drug Metab Dispos 40:2174–2184. https ://doi.org/10.1124/
dmd.112.04753 0
 40. Kaminsky LS, Zhang Z-Y (1997) Human P450 metabolism of 
warfarin. Pharmacol Ther 73:67–74. https ://doi.org/10.1016/
S0163 -7258(96)00140 -4
 41. Wong YWJ, Davis PJ (1989) Microbial models of mammalian 
metabolism: stereoselective metabolism of warfarin in the fun-
gus Cunninghamella elegans. Pharm Res 6:982–987. https ://doi.
org/10.1023/A:10159 05832 184
 42. Olesen OV, Linnet K (1997) Metabolism of the tricyclic anti-
depressant amitriptyline by cDNA-expressed human cytochrome 
P450 enzymes. Pharmacology 55:235–243. https ://doi.
org/10.1159/00013 9533
 43. Zhang D, Evans FE, Freeman JP, Duhart B Jr, Cerniglia CE (1995) 
Biotransformation of amitriptyline by Cunninghamella elegans. 
Drug Metab Dispos 23:1417–1425 (PMID: 8689954)
